Fluticasone Propionate Ointment Rx
Generic Name and Formulations:
Fluticasone propionate 0.005%.
Various generic manufacturers
Indications for Fluticasone Propionate Ointment:
Apply a thin film to affected areas twice daily. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Avoid tight-fitting diapers or plastic pants. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Lotion: avoid excessive sun exposure. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, pruritus, irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, miliaria, erythema, dry skin, excoriation; HPA axis suppression (esp. in children).
Formerly known under the brand name Cutivate.
Crm, oint—contact supplier; Lotion—120mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline